Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
126.70
+0.15 (0.12%)
Jun 5, 2025, 4:00 PM - Market closed
Repligen Revenue
Repligen had revenue of $169.17M in the quarter ending March 31, 2025, with 10.44% growth. This brings the company's revenue in the last twelve months to $650.43M, up 4.88% year-over-year. In the year 2024, Repligen had annual revenue of $634.44M with 0.33% growth.
Revenue (ttm)
$650.43M
Revenue Growth
+4.88%
P/S Ratio
10.91
Revenue / Employee
$365,821
Employees
1,778
Market Cap
7.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 634.44M | 2.08M | 0.33% |
Dec 31, 2023 | 632.36M | -169.17M | -21.11% |
Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RGEN News
- 9 days ago - Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report - GlobeNewsWire
- 4 weeks ago - Repligen Corporation to Present at Upcoming May Investor Conferences - GlobeNewsWire
- 5 weeks ago - Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Repligen Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Repligen Appoints Jacob Johnson As Vice President Investor Relations - GlobeNewsWire
- 2 months ago - Repligen: Ongoing Bioprocessing Market Recovery - Seeking Alpha
- 3 months ago - 908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - Benzinga
- 3 months ago - Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Business Wire